No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Left Ventricular Assist Devices (LVADs) are a specialized subgroup within the cardiovascular devices sector, aimed at supporting patients with advanced heart failure. These mechanical pumps are designed to aid or fully take over the function of the left ventricle, which is the main pumping chamber of the heart. LVADs are typically employed when medical therapy is insufficient, either as a bridge to heart transplantation, a destination therapy for those who are not candidates for a transplant, or increasingly, as a bridge to recovery, where the device supports the heart with the intention that the heart's function might improve to the point that the device can be removed.
The market for LVADs intersects with advancements in battery technology, materials science, and medical device engineering. Over the years, LVADs have progressed from large, volume-restrictive devices to more compact and less invasive units, improving the quality of life for patients. Adoption of these devices is influenced by factors such as the prevalence of heart failure, technological innovations, healthcare infrastructure, as well as reimbursement policies and regulatory approvals.
Some prominent companies in the LVAD market include Abbott Laboratories, which oversees the HeartMate product line, Medtronic, known for their portfolio of cardiac medical devices, and Berlin Heart, which provides options including Excor, a device designed for a range of patient sizes, including pediatric use. Other notable players include Thoratec, which was acquired by St. Jude Medical, itself later acquired by Abbott, and Jarvik Heart, known for Show Less Read more
